Table 1 Patient and tumour characteristics with survival outcome.

From: Differences in prognostic relevance of rectal magnetic resonance imaging findings before and after neoadjuvant chemoradiotherapy

 

No. of Pts.

Overall survival

Disease free survival

Local recurrence rate

5y OS

95% CI

P

5y DFS

95% CI

P

5y LRR

95% CI

p

Sex

   

0.231

  

0.042

  

0.019

   Male

265

86.0

82.0–90.3

 

71.8

66.4–77.6

 

9.1

5.4–12.7

 

   Female

134

88.8

83.6–94.3

 

80.0

73.4–87.2

 

1.7

0.0–4.0

 

Age

   

0.001

  

0.330

  

0.435

   <65

289

88.2

84.6–92.0

 

75.3

70.5–80.5

 

7.3

4.1–10.3

 

   ≥65

110

83.6

77.0–90.8

 

72.5

64.1–82.0

 

4.5

0.0–8.7

 

Location

   

0.065

  

0.029

  

0.094

   >5 cm

274

89.1

85.4–92.8

 

77.4

72.5–82.7

 

4.8

3.1–7.4

 

   ≤5 cm

125

82.4

76.0–89.4

 

68.3

60.4–77.1

 

10.6

4.7–16.1

 

CEA

   

0.003

  

0.008

  

0.102

   ≤5 ng/ml

259

88.0

84.2–92.1

 

77.8

72.7–83.1

 

6.0

2.9–9.1

 

   >5 ng/ml

140

85.0

79.3–91.1

 

68.7

61.2–77.0

 

7.6

3.0–12.0

 

mrT stage

   

0.772

  

0.102

  

0.153

   T3

363

87.1

83.7–90.6

 

76.0

71.6–80.6

 

5.8

3.2–8.3

 

   T4

36

86.1

75.5–98.2

 

61.0

46.9–79.2

 

14.2

1.9–25.0

 

mrN stage

   

0.242

  

0.108

  

0.120

   N0

89

92.1

86.7–97.9

 

81.2

73.0–90.3

 

2.5

0.0–5.9

 

   N1/N2

189/121

85.5

81.7–89.5

 

72.8

67.9–78.0

 

7.7

4.6–10.8

 

mrMRF

   

0.384

  

0.054

  

0.097

   (−)

300

89.0

85.5–92.6

 

77.9

73.2–82.9

 

4.9

2.3–7.5

 

   (+)

99

80.8

73.4–89.0

 

64.6

55.7–74.9

 

11.8

5.0–18.1

 

mrEMVI

   

0.026

  

0.002

  

0.145

   (−)

207

91.8

88.1–95.6

 

80.7

75.3–86.4

 

5.3

2.0–8.4

 

   (+)

192

81.8

76.5–87.4

 

67.9

61.5–75.0

 

8.0

3.9–12.0

 

ymrT

   

0.065

  

0.010

  

0.253

   T0/T1/T2

17/5/107

90.7

85.8–95.9

 

81.9

75.3–89.0

 

5.1

1.0–8.9

 

   T3/T4

239/31

85.2

81.1–89.5

 

71.0

65.7–76.8

 

7.4

4.0–10.6

 

ymrN

   

 < 0.001

  

 < 0.001

  

0.036

   N0

267

91.4

88.1–94.8

 

80.6

75.9–85.6

 

5.3

2.4–8.1

 

   N1/N2

96/36

78.0

71.3–85.4

 

62.5

54.6–71.5

 

9.3

3.9–14.4

 

ymrMRF

   

0.010

  

0.002

  

0.006

   (−)

340

88.8

85.5–92.2

 

77.4

73.0–82.1

 

4.9

2.5–7.3

 

   (+)

59

76.3

66.2–87.9

 

57.9

46.4–72.3

 

16.6

6.1–26.0

 

ymrEMVI

   

 < 0.001

  

 < 0.001

  

0.008

   (−)

302

90.7

87.5–94.1

 

79.3

74.7–84.2

 

5.5

2.8–8.2

 

   (+)

97

75.3

67.1–84.4

 

60.1

51.0–70.8

 

9.9

3.5–15.8

 

mrTRG

   

 < 0.001

  

0.001

  

0.007

   G1/G2/G3

11/79/258

89.7

86.5–92.9

 

77.2

72.8–81.8

 

5.3

2.8–7.7

 

   G4/G5

49/2

68.6

57.0–82.6

 

56.3

43.8–72.5

 

17.2

4.5–28.2

 
  1. 5 y; 5-year, OS; overall survival, DFS; disease free survival, LRR; local recurrence rate, No.; number, Pts.; patients, CI; confidence interval, CEA; carcinoembryonic antigen, mr; magnetic resonance imaging before neoadjuvant chemoradiotherapy, T; tumour stage, N; lymph node stage, MRF; mesorectal fascia involvement, EMVI; extramural venous invasion, ymr; magnetic resonance imaging after neoadjuvant chemoradiotherapy, mrTRG; magnetic resonance tumour regression grade, G; grade.
Back to article page